VENICE, ITALY, May 5, 2019 – Three posters utilizing Myocardial Solutions’ MyoStrain® were presented at the annual European Magnetic Cardiovascular Resonance (EuroCMR) Congress 2019. The event was held in Venice, Italy on May 2-4, 2019. The posters covered the following topics:
- MyoStrain’s ability to quantify subclinical myocardial dysfunction
- A comparison of MyoStrain versus Echocardiography (Ejection Fraction and Global Longitudinal Strain) for detecting cardiotoxicity from cancer therapies
- MyoStrain’s ability to quantify subclinical dysfunction of the right ventricle in patients with pulmonary disease
Links to the posters are provided below:
Citation: Montenbruck, M et al. Fast-SENC segmental intramyocardial strain quantifies subclinical myocardial dysfunction. EuroCMR 2019.
Citation: Steen, H et al. Accuracy of cardiotoxicity detection with fast strain-encoded CMR vs echocardiography. EuroCMR 2019.
Citation: Steen, H et al. Fast-SENC quantifies right ventricular intramyocardial strain to assess RV dysfunction. EuroCMR 2019.
About Myocardial Solutions, Inc.
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.